登瓦夏：全球首款预防登革热二次感染的疫苗。
Dengvaxia: the world's first vaccine for prevention of secondary dengue.
作者信息
Tully Danielle, Griffiths Carrie L
机构信息
Wingate University School of Pharmacy, Levine College of Health Sciences, Wingate, NC, USA.
Wingate University School of Pharmacy, Levine College of Health Sciences, 515 North Main Street, Wingate, NC 28174, USA.
出版信息
Ther Adv Vaccines Immunother. 2021 May 17;9:25151355211015839. doi: 10.1177/25151355211015839. eCollection 2021.
Abstract
The objective of this manuscript was to review and evaluate the efficacy and safety data of Dengvaxia for the treatment of severe secondary dengue infection. Dengvaxia is the brand name for chimeric yellow fever-dengue-tetravalent dengue vaccine (CYD-TDV). A literature search through PubMed was conducted using the keywords 'dengue vaccine', 'Dengvaxia', 'efficacy' or 'safety'. Trials were selected if they appropriately assessed vaccine efficacy or were related to the vaccine approval process for CYD-TDV. Findings from this review underline the evolution of vaccine efficacy against seroprevalence, serotypes, and various ages. There are currently no preventive measures or antiviral treatments for dengue; CYD-TDV is the first vaccine to receive US Food and Drug Administration approval. Protective responses seen with the complete administration of CYD-TDV can become a standardized tool as part of a world vaccination program.
摘要
本手稿的目的是回顾和评估登革热疫苗（Dengvaxia）治疗严重继发性登革热感染的疗效和安全性数据。登革热疫苗（Dengvaxia）是嵌合黄热病-登革热-四价登革热疫苗（CYD-TDV）的商品名。通过PubMed进行文献检索，使用的关键词为“登革热疫苗”、“登革热疫苗（Dengvaxia）”、“疗效”或“安全性”。如果试验适当地评估了疫苗疗效或与CYD-TDV的疫苗批准过程相关，则选择这些试验。本综述的结果强调了疫苗疗效针对血清流行率、血清型和不同年龄的演变。目前尚无登革热的预防措施或抗病毒治疗方法；CYD-TDV是首个获得美国食品药品监督管理局批准的疫苗。完整接种CYD-TDV后出现的保护性反应可成为全球疫苗接种计划一部分的标准化工具。
相似文献
1
Dengvaxia: the world's first vaccine for prevention of secondary dengue.登瓦夏：全球首款预防登革热二次感染的疫苗。
Ther Adv Vaccines Immunother. 2021 May 17;9:25151355211015839. doi: 10.1177/25151355211015839. eCollection 2021.
2
Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9-50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study.健康 9-50 岁人群中简化 CYD-TDV 登革热疫苗接种方案的免疫原性和安全性（CYD65）：一项随机、对照、2 期、非劣效性研究。
Lancet Infect Dis. 2021 Apr;21(4):517-528. doi: 10.1016/S1473-3099(20)30767-2. Epub 2020 Nov 16.
3
Tetravalent Dengue Vaccine: A Review in the Prevention of Dengue Disease.四价登革热疫苗：在登革热疾病预防中的作用评价。
Drugs. 2016 Sep;76(13):1301-1312. doi: 10.1007/s40265-016-0626-8.
4
Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults.采用加速免疫程序的 CYD 四价登革热疫苗的免疫原性：美国成年人的随机 2 期研究。
BMC Infect Dis. 2018 Sep 21;18(1):475. doi: 10.1186/s12879-018-3389-x.
5
Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trial.印度健康成年人中四价登革热疫苗的免疫原性和安全性：一项随机、观察者盲法、安慰剂对照的II期试验。
Hum Vaccin Immunother. 2016;12(2):512-8. doi: 10.1080/21645515.2015.1076598.
6
7
Immunogenicity and safety of a dengue vaccine given as a booster in Singapore: a randomized Phase II, placebo-controlled trial evaluating its effects 5-6 years after completion of the primary series.在新加坡作为加强针接种的登革热疫苗的免疫原性和安全性：一项随机、安慰剂对照的 II 期临床试验，评估其在初级系列完成后 5-6 年内的效果。
Hum Vaccin Immunother. 2020 Mar 3;16(3):523-529. doi: 10.1080/21645515.2019.1661204. Epub 2019 Nov 5.
8
Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.在墨西哥无黄病毒感染史的成年人中评估二价和四价登革热疫苗制剂。
Hum Vaccin Immunother. 2014;10(10):2853-63. doi: 10.4161/21645515.2014.972131.
9
The Effects of Japanese Encephalitis Vaccine and Accelerated Dosing Scheduling on the Immunogenicity of the Chimeric Yellow Fever Derived Tetravalent Dengue Vaccine: A Phase II, Randomized, Open-Label, Single-Center Trial in Adults Aged 18 to 45 Years in the United States.日本脑炎疫苗和加速剂量方案对嵌合黄热衍生四价登革热疫苗免疫原性的影响：美国 18 至 45 岁成年人中进行的 II 期、随机、开放标签、单中心试验。
J Infect Dis. 2020 Mar 16;221(7):1057-1069. doi: 10.1093/infdis/jiz592.
10
Characterization of recombinant yellow fever-dengue vaccine viruses with human monoclonal antibodies targeting key conformational epitopes.用针对关键构象表位的人源单克隆抗体对重组黄热病-登革热疫苗病毒进行鉴定。
Vaccine. 2019 Jul 26;37(32):4601-4609. doi: 10.1016/j.vaccine.2018.04.065. Epub 2018 Apr 26.
引用本文的文献
1
Insect-Specific Flaviviruses Have Potential Applications as a Scaffold for Pathogenic Flavivirus Vaccines.昆虫特异性黄病毒作为致病性黄病毒疫苗的支架具有潜在应用价值。
Vaccines (Basel). 2025 Jul 21;13(7):769. doi: 10.3390/vaccines13070769.
2
Infective capacity of the commercial nematode parasitizing mosquito larvae in Yucatán México.墨西哥尤卡坦半岛寄生蚊虫幼虫的商业线虫的感染能力
Helminthologia. 2024 Dec 12;61(3):254-262. doi: 10.2478/helm-2024-0028. eCollection 2024 Sep.
3
Pathogenicity and virulence of Powassan virus.波瓦桑病毒的致病性和毒力
Virulence. 2025 Dec;16(1):2523887. doi: 10.1080/21505594.2025.2523887. Epub 2025 Jun 26.
4
Multilayer Fluorescent Immunoassay for Early and Sensitive Dengue Virus Detection Using Host and Viral Biomarkers.利用宿主和病毒生物标志物进行早期灵敏登革病毒检测的多层荧光免疫测定法
Bioconjug Chem. 2025 Jul 16;36(7):1474-1482. doi: 10.1021/acs.bioconjchem.5c00153. Epub 2025 Jun 12.
5
Role of c-ABL in DENV-2 Infection and Actin Remodeling in Vero Cells.c-ABL在登革热病毒2型（DENV-2）感染及Vero细胞肌动蛋白重塑中的作用
Int J Mol Sci. 2025 Apr 29;26(9):4206. doi: 10.3390/ijms26094206.
6
Epidemiological dynamics of dengue in Peru: Temporal and spatial drivers between 2000 and 2022.秘鲁登革热的流行病学动态：2000年至2022年的时间和空间驱动因素
PLoS One. 2025 Mar 19;20(3):e0319708. doi: 10.1371/journal.pone.0319708. eCollection 2025.
7
Unraveling the dynamics of dengue in Metahara town, East Shewa, Oromia, Ethiopia, 2023.2023年埃塞俄比亚奥罗米亚州东谢瓦梅塔哈拉镇登革热动态解析
PLoS Negl Trop Dis. 2025 Mar 17;19(3):e0012908. doi: 10.1371/journal.pntd.0012908. eCollection 2025 Mar.
8
Recommendations for dengue vaccine implementation in the elderly population.老年人群登革热疫苗接种建议。
Ther Adv Vaccines Immunother. 2025 Feb 17;13:25151355251321718. doi: 10.1177/25151355251321718. eCollection 2025.
9
Identification of novel inhibitors of dengue viral NS5 RNA-dependent RNA polymerase through molecular docking, biological activity evaluation and molecular dynamics simulations.通过分子对接、生物活性评估和分子动力学模拟鉴定登革病毒NS5 RNA依赖性RNA聚合酶的新型抑制剂。
J Enzyme Inhib Med Chem. 2025 Dec;40(1):2463006. doi: 10.1080/14756366.2025.2463006. Epub 2025 Feb 12.
10
Unraveling the Molecular Mechanisms of Mosquito Salivary Proteins: New Frontiers in Disease Transmission and Control.揭示蚊子唾液蛋白的分子机制：疾病传播与控制的新前沿
Biomolecules. 2025 Jan 8;15(1):82. doi: 10.3390/biom15010082.
本文引用的文献
1
Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial.四价登革热疫苗在 2-17 岁儿童中的安全性和免疫原性：一项随机、安慰剂对照、2 期临床试验。
Lancet. 2020 May 2;395(10234):1434-1443. doi: 10.1016/S0140-6736(20)30556-0. Epub 2020 Mar 17.
2
Dengue.登革热。
Lancet. 2019 Jan 26;393(10169):350-363. doi: 10.1016/S0140-6736(18)32560-1.
3
Four-year safety follow-up of the tetravalent dengue vaccine efficacy randomized controlled trials in Asia and Latin America.四价登革热疫苗在亚洲和拉丁美洲的随机对照临床试验的 4 年安全性随访。
Clin Microbiol Infect. 2018 Jul;24(7):755-763. doi: 10.1016/j.cmi.2018.01.018. Epub 2018 Feb 8.
4
Live-attenuated tetravalent dengue vaccines: The needs and challenges of post-licensure evaluation of vaccine safety and effectiveness.减毒活四价登革热疫苗：疫苗安全性和有效性上市后评估的需求与挑战
Vaccine. 2017 Oct 9;35(42):5535-5542. doi: 10.1016/j.vaccine.2017.08.066.
5
Dissecting Antibodies Induced by a Chimeric Yellow Fever-Dengue, Live-Attenuated, Tetravalent Dengue Vaccine (CYD-TDV) in Naive and Dengue-Exposed Individuals.剖析由嵌合黄热病 - 登革热减毒活四价登革热疫苗（CYD - TDV）在未感染过登革热和曾感染过登革热的个体中诱导产生的抗体。
J Infect Dis. 2017 Feb 1;215(3):351-358. doi: 10.1093/infdis/jiw576.
6
Dengue vaccine: WHO position paper – July 2016.登革热疫苗：世界卫生组织立场文件 - 2016年7月
Wkly Epidemiol Rec. 2016 Jul 29;91(30):349-64.
7
Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and South East Asia.对来自拉丁美洲和东南亚多项2期试验的四价登革热疫苗的免疫反应进行建模。
Vaccine. 2015 Jul 17;33(31):3746-51. doi: 10.1016/j.vaccine.2015.05.059. Epub 2015 Jun 4.
8
Efficacy of a tetravalent dengue vaccine in children in Latin America.四价登革热疫苗在拉丁美洲儿童中的效力。
N Engl J Med. 2015 Jan 8;372(2):113-23. doi: 10.1056/NEJMoa1411037. Epub 2014 Nov 3.
9
Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial.新型四价登革热疫苗在亚洲健康儿童中的临床疗效和安全性：一项 3 期、随机、观察者设盲、安慰剂对照试验。
Lancet. 2014 Oct 11;384(9951):1358-65. doi: 10.1016/S0140-6736(14)61060-6. Epub 2014 Jul 10.
10
Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial.泰国学童中重组、减毒、四价登革热疫苗的保护效力：一项随机、对照 2b 期临床试验。
Lancet. 2012 Nov 3;380(9853):1559-67. doi: 10.1016/S0140-6736(12)61428-7. Epub 2012 Sep 11.
Zotero 插件